PUBLISHER: The Business Research Company | PRODUCT CODE: 1666513
PUBLISHER: The Business Research Company | PRODUCT CODE: 1666513
Conjugate Vaccine Global Market Report 2025
Conjugate vaccines, also referred to as immunogen conjugates, represent advanced immune system modulators extensively employed to induce protection against invading pathogens or stimulate specific antibodies against a targeted molecule. The conjugation process plays a crucial role in augmenting the immune response, enabling a more effective recognition of the pathogen by the immune system.
Two primary types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines consist of a single conjugated antigen, typically designed to target a specific pathogen or strain. These vaccines are utilized for preventing infections caused by bacteria with a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. Monovalent conjugate vaccines are developed to address various diseases, including pneumococcal, influenza, meningococcal, and typhoid. They find application in pediatric and adult patient populations and are utilized in diverse healthcare settings such as hospitals, clinics, homecare, and other medical facilities.
The conjugate vaccine research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The conjugate vaccine market size has grown rapidly in recent years. It will grow from$18.9 billion in 2024 to $21.46 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends
The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $34.59 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity.
The rising use of conjugate vaccines among adults is projected to drive the growth of the conjugate vaccine market. These vaccines are designed to elicit a strong immune response against bacterial capsular polysaccharides, thereby enhancing the body's defense against bacterial infections. Utilizing conjugate vaccines in adults can lower the risk of severe illness, complications, and the transmission of bacterial diseases by stimulating a vigorous immune response. For example, in June 2024, reports from the UK Health Security Agency (UKHSA), a public health organization based in the UK, indicated that the 12-month coverage for the '6-in-1' vaccine in the UK remained steady at 91.7%. The first dose of the pneumococcal conjugate vaccine (PCV) was at 93.7%, while rotavirus coverage increased by 0.6%, reaching 89.3%. Additionally, the second dose of the meningitis B vaccine (MenB2) rose by 0.1% to 91.5%. Thus, the growing use of conjugate vaccines in adults is contributing to the expansion of the conjugate vaccine market.
The increasing prevalence of infectious diseases is anticipated to drive the growth of the conjugate vaccine market. Infectious diseases are conditions caused by pathogenic microorganisms, including bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly from person to person, from animals to humans, or through environmental sources. Conjugate vaccines are essential in preventing infectious diseases caused by specific bacteria, particularly among vulnerable populations such as infants and young children. For example, in November 2023, the World Health Organization (WHO), an international public health agency based in Switzerland, reported that approximately 10.6 million individuals worldwide were diagnosed with tuberculosis (TB) in 2022, including 5.8 million men, 3.5 million women, and 1.3 million children. Therefore, the rising incidence of infectious diseases is fueling the expansion of the conjugate vaccine market.
Innovation in conjugate vaccines emerges as a prominent trend gaining traction in the conjugate vaccine market. Companies actively involved in this market are strategically focused on the development of innovative conjugate vaccines to maintain their competitive standing. An exemplar of this trend is Pfizer Inc., a US-based pharmaceutical and biotechnology company, which, in June 2022, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine is designed to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes covered by PREVNAR 13, along with conjugates for seven additional serotypes associated with invasive pneumococcal disease, characterized by high case-fatality rates, antibiotic resistance, and meningitis.
Major companies operating in the conjugate vaccine market are directing their efforts towards the development of advanced conjugate vaccines, including the 21-valent pneumococcal conjugate vaccine. This type of vaccine is crafted to provide protection against infections caused by Streptococcus pneumoniae bacteria. An illustrative example is Merck & Co., Inc., a US-based pharmaceutical company, which, in April 2022, received the Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its 'V116.' V116 is a 21-valent pneumococcal conjugate vaccine designed for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. Tailored to target strains of pneumococcal bacteria commonly found in adults, V116 represents a significant advancement in conjugate vaccine development.
In August 2022, GSK, a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for $2.1 billion. This strategic move by GSK is aimed at fortifying its portfolio of specialty medicines and vaccines, particularly in the realm of advanced pneumococcal vaccines. The acquisition includes Affinivax's AFX3772, contributing to GSK's position in the development of cutting-edge conjugate vaccines. Affinivax, a US-based biotechnology company, specializes in the development of conjugate vaccines.
Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus
North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Conjugate Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on conjugate vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for conjugate vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The conjugate vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product Type: Monovalent Conjugate Vaccines; Multivalent Conjugate Vaccine
- 2) By Pathogen: Bacterial; Viral
- 3) By Disease Indication: Pneumococcal; Influenza; Meningococcal; Typhoid
- 4) By Patient: Pediatric; Adults
- 5) By End-User: Hospitals; Clinics; Homecare Settings; Other End Users
- Subsegments:
- 1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines
- 2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines; Combination Conjugate Vaccines
- Companies Mentioned: Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Bharat Biotech International Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Conjugate Vaccine Market Characteristics
3. Conjugate Vaccine Market Trends And Strategies
4. Conjugate Vaccine Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market
5. Global Conjugate Vaccine Growth Analysis And Strategic Analysis Framework
- 5.1. Global Conjugate Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Conjugate Vaccine Market Growth Rate Analysis
- 5.4. Global Conjugate Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Conjugate Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Conjugate Vaccine Total Addressable Market (TAM)
6. Conjugate Vaccine Market Segmentation
- 6.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monovalent Conjugate Vaccines
- Multivalent Conjugate Vaccine
- 6.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Bacterial
- Viral
- 6.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pneumococcal
- Influenza
- Meningococcal
- Typhoid
- 6.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pediatric
- Adults
- 6.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Homecare Settings
- Other End Users
- 6.6. Global Conjugate Vaccine Market, Sub-Segmentation Of Monovalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Single Pathogen Conjugate Vaccines
- 6.7. Global Conjugate Vaccine Market, Sub-Segmentation Of Multivalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Multiple Pathogen Conjugate Vaccines
- Combination Conjugate Vaccines
7. Conjugate Vaccine Market Regional And Country Analysis
- 7.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Conjugate Vaccine Market
- 8.1. Asia-Pacific Conjugate Vaccine Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Conjugate Vaccine Market
- 9.1. China Conjugate Vaccine Market Overview
- 9.2. China Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Conjugate Vaccine Market
- 10.1. India Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Conjugate Vaccine Market
- 11.1. Japan Conjugate Vaccine Market Overview
- 11.2. Japan Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Conjugate Vaccine Market
- 12.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Conjugate Vaccine Market
- 13.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Conjugate Vaccine Market
- 14.1. South Korea Conjugate Vaccine Market Overview
- 14.2. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Conjugate Vaccine Market
- 15.1. Western Europe Conjugate Vaccine Market Overview
- 15.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Conjugate Vaccine Market
- 16.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Conjugate Vaccine Market
- 17.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Conjugate Vaccine Market
- 18.1. France Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Conjugate Vaccine Market
- 19.1. Italy Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Conjugate Vaccine Market
- 20.1. Spain Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Conjugate Vaccine Market
- 21.1. Eastern Europe Conjugate Vaccine Market Overview
- 21.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Conjugate Vaccine Market
- 22.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Conjugate Vaccine Market
- 23.1. North America Conjugate Vaccine Market Overview
- 23.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Conjugate Vaccine Market
- 24.1. USA Conjugate Vaccine Market Overview
- 24.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Conjugate Vaccine Market
- 25.1. Canada Conjugate Vaccine Market Overview
- 25.2. Canada Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Conjugate Vaccine Market
- 26.1. South America Conjugate Vaccine Market Overview
- 26.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Conjugate Vaccine Market
- 27.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Conjugate Vaccine Market
- 28.1. Middle East Conjugate Vaccine Market Overview
- 28.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Conjugate Vaccine Market
- 29.1. Africa Conjugate Vaccine Market Overview
- 29.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Conjugate Vaccine Market Competitive Landscape And Company Profiles
- 30.1. Conjugate Vaccine Market Competitive Landscape
- 30.2. Conjugate Vaccine Market Company Profiles
- 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bharat Biotech International Limited Overview, Products and Services, Strategy and Financial Analysis
31. Conjugate Vaccine Market Other Major And Innovative Companies
- 31.1. Serum Institute of India Private Limited
- 31.2. Biological E. Limited
- 31.3. Bavarian Nordic A/S
- 31.4. CSL Limited
- 31.5. Novartis AG
- 31.6. GreenSignal Bio Pharma Limited
- 31.7. Taj Pharmaceuticals Limited
- 31.8. Vaxcyte Inc.
- 31.9. Neuron Biotech Co. Ltd.
- 31.10. Bio-Med Pvt. Ltd.
- 31.11. Sinovac Biotech Ltd.
- 31.12. Takeda Pharmaceutical Company Limited
- 31.13. Valneva SE
- 31.14. Dynavax Technologies Corporation
- 31.15. Emergent BioSolutions Inc.
32. Global Conjugate Vaccine Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Conjugate Vaccine Market
34. Recent Developments In The Conjugate Vaccine Market
35. Conjugate Vaccine Market High Potential Countries, Segments and Strategies
- 35.1 Conjugate Vaccine Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Conjugate Vaccine Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Conjugate Vaccine Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
